Supplement × Prescription·a synergy·Insufficient evidence

Coenzyme Q10 + Evolocumab

Synergy Insufficient evidence

Coenzyme Q10 (ubiquinone) is sometimes used by patients on lipid-lowering therapy because of concerns about statin-associated muscle symptoms. Evolocumab is a PCSK9 inhibitor monoclonal antibody and, unlike statins, does not deplete the mevalonate pathway and is not associated with myopathy or reductions in endogenous CoQ10. There is no pharmacokinetic interaction between CoQ10 and evolocumab. Co-use is benign, but CoQ10 should not be expected to add meaningful LDL-lowering or to mitigate a side effect that evolocumab does not cause.

From the database

What the row says.

Every entry follows the same shape: what is happening, the mechanism, and the recommendation.

Substances
Pair type
Synergy
Evidence
Insufficient
Source citations
2
Scope
Supplement × Prescription
Last verified
June 4, 2026
SynergyInsufficient evidence

What is happening. Coenzyme Q10 (ubiquinone) is sometimes used by patients on lipid-lowering therapy because of concerns about statin-associated muscle symptoms. Evolocumab is a PCSK9 inhibitor monoclonal antibody and, unlike statins, does not deplete the mevalonate pathway and is not associated with myopathy or reductions in endogenous CoQ10. There is no pharmacokinetic interaction between CoQ10 and evolocumab. Co-use is benign, but CoQ10 should not be expected to add meaningful LDL-lowering or to mitigate a side effect that evolocumab does not cause.

Mechanism. No shared metabolic or pharmacokinetic pathway. Evolocumab is a subcutaneously injected monoclonal antibody cleared by proteolysis and target-mediated disposition (binding to PCSK9), not by CYP enzymes or hepatic transporters; CoQ10 is absorbed enterally and used in mitochondrial electron transport. The two do not interact.

Recommendation. No interaction-based restriction. CoQ10 may be continued if a patient takes it, but it is not required with evolocumab and does not address any evolocumab-specific risk. Do not substitute CoQ10 for evidence-based LDL-lowering therapy.

Stack Score

How it moves the number.

Effect on the composite score

If both Coenzyme Q10 and Evolocumab are in the same stack, this pair applies +2 to your Stack Score (per scored synergy row).

The full algorithm, the clamping rules, and four worked stacks are at /methodology/stack-score.

Sources

Sources, by evidence tier.

Every claim on this page is cited. PMIDs link straight to PubMed.

Reference material

2
  • 1Sabatine MS, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017.Needs sourceNo link
  • 2Banach M, et al. Statin therapy and plasma coenzyme Q10 concentrations - a systematic review and meta-analysis. Pharmacol Res. 2015.Needs sourceNo link

Check your full routine

One pair was the worked example.

Drop your supplements and prescriptions into NutriStack and it runs every pair at once: every interaction, synergy, timing rule, and contraindication, each linked to its primary source.

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.